Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Physical Medicine and Rehabilitation · Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder

Do hEDS and HSD Get Worse Over Time? Long-Term Outlook

At a Glance

hEDS and HSD do not inevitably worsen in a steady, predictable way. Symptoms fluctuate with age, activity, stress, illness, and hormones; individualized rehabilitation and pacing can support function, and there is no strong evidence that either condition shortens life expectancy.

Does hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD) inevitably get worse over time? Observational evidence and clinical consensus suggest that these conditions do not follow a uniformly predictable or inevitable downward trajectory [1]. While hEDS and HSD can cause substantial, lifelong challenges with pain, fatigue, and joint instability, a variable course is common [1]. Treatment focuses on supporting function and quality of life, and many people report subjective improvement in symptoms with individualized rehabilitation and pacing [2].

It is important to note that hEDS is a clinical diagnosis, while HSD is a broader umbrella term for symptomatic joint hypermobility. Research often groups them together, but your individual course may vary depending on your specific symptoms and overlap with other conditions.

The Variable Course of Hypermobility

Rather than a steady, inevitable decline, the natural history of hEDS and HSD is often characterized by fluctuations. You may experience “flares,” where symptoms temporarily worsen due to an acute injury, illness, stress, or hormonal changes [1].

As you age, the way hypermobility affects your body may change. While joint flexibility often naturally decreases (stiffens) as people get older, this does not mean the underlying connective tissue condition has resolved [1]. Older adults with hEDS and HSD frequently continue to experience pain, fatigue, orthostatic symptoms (like dizziness upon standing), and gastrointestinal issues [3][4]. However, long-term observational studies suggest that while people with hEDS or HSD may have lower baseline muscle strength, this strength does not necessarily decline at a faster rate over time compared to people without the condition [5].

What Can Change Over Time?

  • Joint Range of Motion: May decrease naturally with age, leading to a feeling of stiffness rather than looseness.
  • Pain and Instability: Often fluctuate with activity levels, stress, or hormonal shifts (such as menopause).
  • Muscle Conditioning: Can decline if fear of injury leads to prolonged inactivity, worsening joint instability.

Supporting Function Over Time

Because the course is variable, treatment focuses on supporting your physical function and minimizing symptom flares. Observational studies suggest that therapeutic exercise and motor-function training can be beneficial [6][7]. In one real-world study of adults with hEDS/HSD, 54% reported feeling subjectively better after roughly 20 months of coordinated physical therapy [2]. However, no single treatment guarantees improvement, and needing mobility aids, accommodations, or pain management is a valid part of taking care of yourself, not a sign of failure.

To support your joints and energy levels:

  • Condition-Specific Rehabilitation: Working with a physical therapist can help you build strength, endurance, proprioception (body awareness), and motor control to stabilize joints [6]. Therapists should help you avoid rapid progression, uncontrolled heavy loading, and repeated end-range stretching, which can cause treatment-related injuries [8][9].
  • Pacing and Rest: Balancing daily activities helps avoid the “push-crash” cycle [10]. If you experience post-exertional malaise (a severe worsening of symptoms after physical or mental effort) or significant orthostatic intolerance (dizziness/racing heart when upright), your activity plan must be carefully adapted to include necessary rest [8][11].

Life Expectancy: hEDS vs. Vascular EDS

It is common to encounter alarming statistics about EDS online, but it is vital to distinguish between hEDS/HSD and Vascular Ehlers-Danlos Syndrome (vEDS).

vEDS is a distinct, rare genetic condition (typically involving the COL3A1 gene) characterized by extreme fragility of blood vessels and hollow organs [12]. People with vEDS face a high risk of life-threatening complications, such as early spontaneous arterial or digestive ruptures. Historical cohorts placed median life expectancy around 40 to 50 years, though this is a population estimate and not an individual prediction [13][14].

In contrast, there is no strong evidence that hEDS or HSD alone shortens life expectancy [13][15]. While some people with hEDS or HSD may have mild dilation of the aortic root (the start of the main artery from the heart), this is generally mild [15]. Not everyone requires lifelong cardiac imaging. A clinician may recommend a baseline echocardiogram based on your physical exam, personal or family history, or symptoms; whether you need repeat imaging depends entirely on those individualized findings [15][16].

When Worsening Symptoms Need a Fresh Look

Because hEDS and HSD do not typically cause rapid, irreversible deterioration, you should never assume a sudden, severe worsening of health is just part of the condition.

Other factors that require specific clinical evaluation include:

  • Autonomic and Immunologic Conditions: Postural Orthostatic Tachycardia Syndrome (POTS) and conditions like Mast Cell Activation Syndrome (MCAS) are sometimes seen in people with hypermobility [17]. However, ordinary dizziness or fatigue does not automatically mean you have POTS, and MCAS requires specific diagnostic testing rather than just symptom overlap [17].
  • Gastrointestinal Issues: Common causes of severe nausea or abdominal pain should be evaluated first. While rare motility issues or vascular compression syndromes can occur, a symptom-based evaluation is required to rule out standard gastrointestinal diseases [17][18].
  • Alternative Diagnoses: If you develop atypical features—such as unexpected inflammatory signs, unusual skin fragility, or new vascular features—your doctor may need to reassess your diagnosis. Some people initially diagnosed with hEDS are later found to have other heritable connective tissue disorders that require different management [19].

🚨 When to Seek Emergency Care

Most symptom flares are not dangerous, but certain symptoms require immediate emergency assessment rather than a routine clinic visit [12][20]:

  • Sudden, severe chest, abdominal, or back pain
  • Fainting or collapsing
  • New severe weakness, numbness, or difficulty speaking
  • Severe shortness of breath
  • Significant or unexplained bleeding
  • An acutely injured joint with loss of circulation, loss of sensation, or an inability to bear weight

Common questions in this guide

Do hEDS and HSD inevitably get worse as I age?
No. hEDS and HSD often have a variable course rather than a steady, predictable decline, with flares related to activity, stress, illness, or hormonal changes. Symptoms can remain significant, but individualized rehabilitation and pacing may improve function and quality of life.
What does aging typically do to hEDS and HSD symptoms?
Joint range of motion often decreases naturally with age, so some people feel stiffer rather than more flexible. This does not mean the underlying connective-tissue condition has resolved; pain, fatigue, dizziness when upright, and gastrointestinal symptoms may continue.
Can physical therapy help my long-term outlook with hEDS or HSD?
Individualized physical therapy can build strength, endurance, body awareness, and motor control to support joint stability. Progress should be gradual and paired with pacing; people with post-exertional malaise or significant orthostatic intolerance may need a specially adapted activity plan, and improvement is not guaranteed.
Does hEDS or HSD shorten life expectancy?
Current evidence does not show that hEDS or HSD alone shortens life expectancy. These conditions are distinct from vascular EDS, which involves greater fragility of blood vessels and hollow organs and has a different risk profile.
When should new or worsening symptoms be checked urgently?
Sudden severe chest, abdominal, or back pain, fainting, new severe weakness or numbness, trouble speaking, severe shortness of breath, unexplained significant bleeding, or an injured joint with loss of circulation or sensation requires emergency assessment. A persistent or atypical change should also be reviewed by a clinician rather than automatically attributed to hEDS or HSD.
Will I need an echocardiogram if I have hEDS or HSD?
Not everyone with hEDS or HSD needs lifelong heart imaging. A clinician may recommend a baseline echocardiogram based on your examination, symptoms, or personal or family history, and the need for repeat imaging depends on those findings.

Get notified when new evidence is published on hypermobility syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Clinical trajectory of hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders in older adults.

    Anderson LK, Lane KR

    Journal of the American Association of Nurse Practitioners 2023; (35(10)):605-612 doi:10.1097/JXX.0000000000000900.

    PMID: 37261967
  2. 2

    Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?

    Aubry-Rozier B, Schwitzguebel A, Valerio F, et al.

    Rheumatology international 2021; (41(10)):1785-1794 doi:10.1007/s00296-021-04968-3.

    PMID: 34398260
  3. 3

    Health-Related Quality of Life in Midlife and Older Women With Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

    Anderson LK

    Nursing for women's health 2026; (30(2)):85-92 doi:10.1016/j.nwh.2025.09.006.

    PMID: 41587761
  4. 4

    Hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders in older women: A feasibility study.

    Anderson LK, Lane KR

    Musculoskeletal care 2023; (21(3)):741-748 doi:10.1002/msc.1747.

    PMID: 36864687
  5. 5

    Does Muscle Strength Change Over Time in Patients With Hypermobile Ehlers-Danlos Syndrome/Hypermobility Spectrum Disorder? An Eight-Year Follow-Up Study.

    Coussens M, Calders P, Lapauw B, et al.

    Arthritis care & research 2021; (73(7)):1041-1048 doi:10.1002/acr.24220.

    PMID: 32293111
  6. 6

    Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome: a scoping review.

    Garreth Brittain M, Flanagan S, Foreman L, Teran-Wodzinski P

    Disability and rehabilitation 2024; (46(10)):1936-1953 doi:10.1080/09638288.2023.2216028.

    PMID: 37231592
  7. 7

    Home-based exercise therapy for treating shoulder instability in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. A randomized trial.

    Spanhove V, De Wandele I, Malfait F, et al.

    Disability and rehabilitation 2023; (45(11)):1811-1821 doi:10.1080/09638288.2022.2076932.

    PMID: 35609204
  8. 8

    Exercise beliefs and behaviours of individuals with Joint Hypermobility syndrome/Ehlers-Danlos syndrome - hypermobility type.

    Simmonds JV, Herbland A, Hakim A, et al.

    Disability and rehabilitation 2019; (41(4)):445-455 doi:10.1080/09638288.2017.1398278.

    PMID: 29125009
  9. 9

    Managing Patients With Hypermobility Disorders: They've Seen You, but Have You Seen Them?

    Mintken PE, Dommerholt J, Francomano CA

    The Journal of orthopaedic and sports physical therapy 2026; (56(8)):478-481 doi:10.2519/jospt.2026.13979.

    PMID: 42538787
  10. 10

    Developing a self-management intervention to manage hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS): an analysis informed by behaviour change theory.

    Bennett SE, Walsh N, Moss T, Palmer S

    Disability and rehabilitation 2022; (44(18)):5231-5240 doi:10.1080/09638288.2021.1933618.

    PMID: 34101520
  11. 11

    Dysautonomia in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders is associated with exercise intolerance and cardiac atrophy.

    Ruiz Maya T, Fettig V, Mehta L, et al.

    American journal of medical genetics. Part A 2021; (185(12)):3754-3761 doi:10.1002/ajmg.a.62446.

    PMID: 34331416
  12. 12

    Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome.

    Byers PH, Belmont J, Black J, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(1)):40-47 doi:10.1002/ajmg.c.31553.

    PMID: 28306228
  13. 13

    Ruptured ulnar artery aneurysm in vascular Ehlers-Danlos syndrome.

    Howard R, Osborne N

    Journal of vascular surgery cases and innovative techniques 2020; (6(1)):71-74 doi:10.1016/j.jvscit.2019.11.013.

    PMID: 32072093
  14. 14

    The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome.

    Frank M, Albuisson J, Ranque B, et al.

    European journal of human genetics : EJHG 2015; (23(12)):1657-64 doi:10.1038/ejhg.2015.32.

    PMID: 25758994
  15. 15

    Cardiovascular manifestations of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Rashed ER, Ruiz Maya T, Black J, et al.

    Vascular medicine (London, England) 2022; (27(3)):283-289 doi:10.1177/1358863X211067566.

    PMID: 35000503
  16. 16

    Longitudinal echocardiography in pediatric patients with hypermobile Ehlers-Danlos syndrome.

    Lahey H, Shin H, Myers K, McBride KL

    American journal of medical genetics. Part A 2024; (194(12)):e63844 doi:10.1002/ajmg.a.63844.

    PMID: 39148461
  17. 17

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  18. 18

    Mast cell activation and nutritional disorders in patients with hypermobility.

    Penny HA, Aziz I, Lam C

    Current opinion in gastroenterology 2024; (40(3)):225-232 doi:10.1097/MOG.0000000000001008.

    PMID: 38393310
  19. 19

    Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.

    Forghani I, See J, McGonigle WC

    Genes 2025; (16(5)) doi:10.3390/genes16050530.

    PMID: 40428350
  20. 20

    Spontaneous pneumothorax and hemothorax frequently precede the arterial and intestinal complications of vascular Ehlers-Danlos syndrome.

    Shalhub S, Neptune E, Sanchez DE, et al.

    American journal of medical genetics. Part A 2019; (179(5)):797-802 doi:10.1002/ajmg.a.61094.

    PMID: 30793832

This page explains the variable long-term course of hEDS and HSD for informational purposes only and does not replace medical advice. Discuss symptom changes, testing, and emergency concerns with your healthcare professional.